Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
- Japan Offers Mpox Vaccines to Columbia for Free
December 8, 2022
- Man Sues PMDA over Rejected Relief Claim for “Ranitidine Caused Cancer”
December 7, 2022
- Lilly’s Insulin Lyumjev Gets Label Update for Pediatric Use
December 7, 2022
- Delete Contraindications on Use of Amlodipine, Nifedipine in Pregnant Women: MHLW
December 6, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- PAFSC Committee OKs Plan to Monitor Early Safety Signals from Xocova Using MID-NET
December 5, 2022
- LDP Committee Underscores Critical Situation of Drugs in Off-Year Discussions
December 5, 2022
- NHI-Market Price Gap Narrowed, but Chuikyo Payer Reps Say Normal Revision Possible
December 5, 2022
- LDP Project Team Submits Proposal, Calls for Limiting Off-Year Coverage to Drugs with Larger-than-Average Price Gap
December 5, 2022
- Japan Enacts Bill to Amend Infectious Disease Act
December 5, 2022
- Japan Enacts FY2022 Extra Budget, Reserves Nearly 4 Trillion Yen for COVID Response, Medical DX, Childcare
December 5, 2022
- Industry Hews to “No” to Off-Year Plan, but Wants Special Steps If It Is to Happen: LDP Confab
December 2, 2022
- Finance Minister Says Wants to “Reduce People’s Burdens” via Drug Price Revision
December 2, 2022
- Average NHI-Market Price Gap for 2023 Off-Year Revision at 7.0%: MHLW
December 2, 2022
- Japan Plans to Lower Minimum Age for Moderna COVID Booster to 12
December 2, 2022
- Evusheld Shelf Life Extended for 6 Months in Japan
December 1, 2022
- MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…